Report – Strategic PAI Readiness: A Data-Driven Approach for Pharma Sponsors and Manufacturers
White Paper – Agentic AI: Transforming Life Sciences Quality and Regulatory with Actionable Intelligence
Report - Access the Full FDA Form 483
Report – A Deeper Dive into FDA’s Newly Published Complete Response Letters (CRLs)
Report – Key Insights from CDER Warning Letters: Hot Topics and Trends
Report - Analysis of FDA 483 issued to Cipla Limited
Report – Analysis of FDA 483 issued to Jiangsu Hengrui Pharmaceuticals
Report - Aurobindo’s Quality Problems: A Timeline of Regulatory Actions and Recalls
Report – First FDA Warning Letter to Excipient Manufacturer Provides Lessons
Report – Intas Pharmaceuticals’ Troubles with FDA Continue
Report – Expert Analysis: 22 years of FDA Drug GMP 483s
Report – Analysis of FDA 483s Issued to Excipient Manufacturers Since 2000
Report – Analysis of FDA Drug GMP Warning Letters for FY2022
Report – Breaking News: The First FDA Warning Letter to an Excipient Manufacturer
Report – Insights on Quality from FDA Leaders
Report – Wipe it With a Cloth? Particle Contamination Risks of Cloth Wipes
Report - 4 GMP Case Studies Including FDA Findings and Concerns
Report – Analysis of 2021 U.S FDA 483 GMP Observations
Report – Yes, Warehouses that Store and Distribute FDA Regulated Products Must Comply with Relevant GMPs
Report – UDI - related Issues in Form 483s: Where Should You Focus Mitigation Efforts?
Report – Analysis of FDA Drug GMP Warning Letters for FYs 2020 and 2021
Report – GMP Issues With COVID Vaccines and Drugs are Not New Concerns
Report – The Current Pharmaceutical Quality Landscape
Report – An In-Depth Look at Combination Product Regulations
Report – 5 GMP Case Studies
Report – 483 Data Integrity Observations
Report – Analysis of 2019 UK MHRA GMP Inspection Findings
Report – FDA FY2020 Drug Observations and Trends
Report – FDA Inspection Landscape Mid-2020 and Virtual Inspections
Report – State of Pharmaceutical Quality
